Published in J Immunol Methods on December 27, 2010
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
A Functional Role for Antibodies in Tuberculosis. Cell (2016) 2.17
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest (2013) 1.60
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. PLoS Pathog (2016) 1.43
HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science (2015) 1.43
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis (2012) 1.21
High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods (2012) 1.12
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe (2016) 1.09
Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J Virol (2013) 1.08
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J Virol (2011) 0.99
Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J Virol (2013) 0.98
Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. PLoS Pathog (2016) 0.96
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96
New concepts in HIV-1 vaccine development. Curr Opin Immunol (2016) 0.94
Which Antibody Functions are Important for an HIV Vaccine? Front Immunol (2014) 0.94
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio (2016) 0.94
Neutrophil-Mediated Phagocytosis of Staphylococcus aureus. Front Immunol (2014) 0.93
Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One (2012) 0.92
Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One (2014) 0.92
Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. PLoS Pathog (2015) 0.91
HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One (2014) 0.91
Chemically synthesized molecules with the targeting and effector functions of antibodies. J Am Chem Soc (2014) 0.89
Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS (2014) 0.88
Determining the phagocytic activity of clinical antibody samples. J Vis Exp (2011) 0.87
Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity. PLoS One (2015) 0.87
Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol (2014) 0.86
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog (2016) 0.86
Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques. J Virol (2016) 0.83
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clin Immunol (2014) 0.83
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity. Mol Ther Nucleic Acids (2013) 0.82
Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J Virol (2013) 0.82
Influenza-Specific Antibody-Dependent Phagocytosis. PLoS One (2016) 0.81
Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques. J Virol (2016) 0.81
Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol (2016) 0.81
Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees. PLoS Comput Biol (2015) 0.80
Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. J Immunol (2015) 0.79
Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol (2016) 0.78
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates. JCI Insight (2016) 0.77
B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques. J Immunol (2016) 0.77
High yield purification of Plasmodium falciparum merozoites for use in opsonizing antibody assays. J Vis Exp (2014) 0.77
Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T Cells. J Immunol (2016) 0.76
Systems serology for evaluation of HIV vaccine trials. Immunol Rev (2017) 0.76
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Open Forum Infect Dis (2016) 0.76
High EBV load and genomic diversity are associated with generation of gp350 specific neutralizing antibodies following Acute Infectious Mononucleosis. J Virol (2016) 0.75
Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods (2017) 0.75
Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques. Clin Immunol (2015) 0.75
Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol (2016) 0.75
Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. J Virol (2017) 0.75
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. J Virol (2016) 0.75
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat Commun (2017) 0.75
Novel cross-reactive monoclonal antibodies against Ebolavirus glycoproteins show protection in a murine challenge model. J Virol (2017) 0.75
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity Against SHIV in Rhesus Monkeys. J Virol (2017) 0.75
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer (1980) 10.11
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med (1977) 7.01
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res (1982) 4.98
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol (1990) 2.47
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol (2003) 1.82
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol (2006) 1.77
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther (2008) 1.61
Fc receptors and their interaction with complement in autoimmunity. Immunol Lett (2005) 1.60
Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta (2005) 1.56
Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin Exp Immunol (2002) 1.48
EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect Immun (2002) 1.42
The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. J Leukoc Biol (1991) 1.40
Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One (2008) 1.37
Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res (2006) 1.34
The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol (1995) 1.29
Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol (1996) 1.26
Contribution of phagocytosis and intracellular sensing for cytokine production by Staphylococcus aureus-activated macrophages. Infect Immun (2006) 1.19
Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol (2008) 1.16
Fasciola hepatica: parasite-secreted proteinases degrade all human IgG subclasses: determination of the specific cleavage sites and identification of the immunoglobulin fragments produced. Exp Parasitol (2000) 1.11
Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology (1991) 1.06
Phagocytosis of gram-negative bacteria by a unique CD14-dependent mechanism. J Leukoc Biol (1997) 1.04
High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol (1995) 1.01
Phagocytosis of Mycobacterium tuberculosis or particulate stimuli by human monocytic cells induces equivalent monocyte chemotactic protein-1 gene expression. Cytokine (1993) 1.00
Effect of immune status on dengue 2 virus replication in cultured leukocytes from infants and children. Infect Immun (1979) 0.92
Monocyte p110alpha phosphatidylinositol 3-kinase regulates phagocytosis, the phagocyte oxidase, and cytokine production. J Leukoc Biol (2007) 0.92
Differential cytokine gene expression and secretion after phagocytosis by a human monocytic cell line of Toxoplasma gondii compared with Mycobacterium tuberculosis. Clin Exp Immunol (1993) 0.91
Regulation of IL-10 secretion after phagocytosis of Mycobacterium tuberculosis by human monocytic cells. Cytokine (2000) 0.90
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. Mol Immunol (2007) 0.87
Production of proinflammatory cytokines by phorbol myristate acetate-treated THP-1 cells and monocyte-derived macrophages after phagocytosis of apoptotic CTLL-2 cells. J Immunol (1998) 0.86
Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III. Ann Hematol (1997) 0.86
Nitric oxide production in human macrophagic cells phagocytizing opsonized zymosan: direct characterization by measurement of the luminol dependent chemiluminescence. Free Radic Res (1998) 0.82
Phenotypic alterations and cytokine production in THP-1 cells in response to allergens. Toxicol In Vitro (2006) 0.81
Discriminating between protective and enhancing HIV antibodies. AIDS Res Hum Retroviruses (1990) 0.81
Antibody dependent cellular cytotoxicity (ADCC)-reaction and an in vitro steroid sensitivity test of peripheral lymphocytes in children with malignant haematological and autoimmune diseases. Acta Paediatr Hung (1986) 0.81
Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infect Immun (2005) 0.78
[IgA protease activity of microbes in the genus Bordetella]. Zh Mikrobiol Epidemiol Immunobiol (1985) 0.78
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
Toward an AIDS vaccine. Science (2008) 4.83
Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater (2008) 4.81
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol (2004) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol (2004) 3.21
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol (2007) 2.77
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater (2011) 2.71
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods (2008) 2.56
Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest (2012) 2.55
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Co-regulation of cell adhesion by nanoscale RGD organization and mechanical stimulus. J Cell Sci (2002) 2.42
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A (2011) 2.37
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov (2011) 2.32
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17